Evidence map›Paper›PMID 30172236›Full record

ArticleBiosensors & bioelectronics2018

Integrated LAMP and immunoassay platform for diarrheal disease detection.

Christopher R Phaneuf, Betty Mangadu, Huu M Tran, Yooli K Light, Anchal Sinha, Frank W Charbonier, Tyler P Eckles, Anup K Singh, Chung-Yan Koh

Open access · hybridAbstract read
In one paragraph

Article in Biosensors & bioelectronics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Christopher R PhaneufBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Betty MangaduBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Huu M TranBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Yooli K LightSystems Biology, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Anchal SinhaBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Frank W CharbonierBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Tyler P EcklesBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Anup K SinghBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States.
Chung-Yan KohBiotechnology and Bioengineering, Sandia National Laboratories, 7011 East Avenue, Livermore, CA 94550, United States. Electronic address: ckoh@sandia.gov.
Sandia National Laboratories California · US

Funding

Microfluidic Platform for Multiplexed DiagnosticsR01AI098853 · NIAID · SANDIA CORP-SANDIA NATIONAL LABORATORIES · PI SINGH, ANUP K. · 2012 to 2015
$3.5M
NIAID NIH HHS R01 AI098853
6 · The paper itself

Abstract

The challenges of diagnosing infectious disease, especially in the developing world, and the shortcomings of available instrumentation have exposed the need for portable, easy-to-use diagnostic tools capable of detecting the wide range of causative microbes while operating in low resource settings. We present a centrifugal microfluidic platform that combines ultrasensitive immunoassay and isothermal amplification-based screening for the orthogonal detection of both protein and nucleic acid targets at the point-of-care. A disposable disc with automatic aliquoting inlets is paired with a non-contact heating system and precise rotary control system to yield an easy-to-use, field-deployable platform with versatile screening capabilities. The detection of three enterotoxins (cholera toxin, Staphylococcal enterotoxin B, and Shiga-like toxin 1) and three enteric bacteria (C. jejuni, E. coli, and S. typhimurium) were performed independently and shown to be highly sensitive (limit of detection = 1.35-5.50 ng/mL for immunoassays and 1-30 cells for isothermal amplification), highly exclusive in the presence of non-specific targets, and capable of handling a complex sample matrix like stool. The full panel of toxins and bacteria were reliably detected simultaneously on a single disc at clinically relevant sample concentrations in less than an hour. The ability of our technology to detect multiple analyte types in parallel at the point-of-care can serve a variety of needs, from routine patient care to outbreak triage, in a variety of settings to reduce disease impact and expedite effective treatment.

Indexed as

ImmunoassayNucleic Acid Amplification TechniquesBiosensing TechniquesDiarrheaEnterobacteriaceaeEnterotoxinsFecesHumansLimit of DetectionMicrofluidicsEnterotoxinsCentrifugalEnteric pathogensImmunoassayIsothermal amplificationLAMPMicrofluidicsPoint-of-care

Identifiers

PMID30172236
PMCPMC6145809
OpenAlexW2887404714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.